Lunelax 3.3 g/ dose নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

lunelax 3.3 g/ dose

mylan healthcare norge as - ispaghulafrøskall - pulver - 3.3 g/ dose

Evusheld ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

evusheld

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Lunelax 3.3 g/ dose নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

lunelax 3.3 g/ dose

meda - asker - ispaghulafrøskall - pulver - 3.3 g/ dose

Lucentis ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

lucentis

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - Øyemidler - lucentis er angitt i voksne for:behandling av neovascular (våt) aldersrelatert makuladegenerasjon (amd)behandling av synshemming på grunn av choroidal neovascularisation (cnv)behandling av synshemming på grunn diabetiker macular ødemer (dme)behandling av synshemming på grunn av flekker ødemer sekundært til retinal vene okklusjon (gren rvo eller sentrale rvo).

Clamoxyl vet 510 mg/ g নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

clamoxyl vet 510 mg/ g

zoetis finland oy - amoksicillintrihydrat - pulver til bruk i drikkevann - 510 mg/ g

Resonium-Calcium 1 g/ g নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

resonium-calcium 1 g/ g

sanofi-aventis norge (3) - kalsiumpolystyrensulfonat - pulver til mikstur/rektalvæske, suspensjon - 1 g/ g

Byooviz ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - Øyemidler - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ximluci ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ranivisio ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Eylea ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

eylea

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - Øyemidler - eylea er indikert for voksne for behandling av:neovascular (våt) aldersrelatert makuladegenerasjon (amd);synshemming på grunn av flekker ødemer sekundært til retinal vene okklusjon (gren rvo eller sentrale rvo);synshemming på grunn diabetiker macular ødemer (dme);synshemming på grunn av begrenset choroidal neovascularisation (nærsynt cnv).